Inogen (INGN) – Analysts’ Weekly Ratings Updates

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of Inogen (NASDAQ: INGN) recently:

  • 8/9/2019 – Inogen was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/8/2019 – Inogen had its “market perform” rating reaffirmed by analysts at Svb Leerink Llc. They now have a $47.00 price target on the stock, down previously from $78.00.
  • 8/8/2019 – Inogen was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating.
  • 8/7/2019 – Inogen had its price target lowered by analysts at Piper Jaffray Companies from $140.00 to $80.00. They now have an “overweight” rating on the stock.
  • 8/7/2019 – Inogen had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 8/7/2019 – Inogen was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $48.00 price target on the stock, down previously from $85.00.
  • 8/7/2019 – Inogen was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating.
  • 7/27/2019 – Inogen was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/3/2019 – Inogen was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $72.00 price target on the stock.
  • 6/28/2019 – Inogen was downgraded by analysts at Needham & Company LLC from a “strong-buy” rating to a “buy” rating. They now have a $91.00 price target on the stock, down previously from $111.00.

Shares of NASDAQ:INGN traded down $0.94 on Tuesday, hitting $45.47. 449,900 shares of the company traded hands, compared to its average volume of 585,713. Inogen Inc has a 52 week low of $41.19 and a 52 week high of $287.79. The company has a quick ratio of 6.82, a current ratio of 7.35 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $53.88 and a 200-day simple moving average of $79.84. The company has a market cap of $1.02 billion, a PE ratio of 19.77, a PEG ratio of 2.64 and a beta of 1.40.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). Inogen had a net margin of 11.24% and a return on equity of 13.34%. The company had revenue of $101.10 million for the quarter, compared to the consensus estimate of $106.88 million. During the same quarter in the previous year, the business earned $0.65 earnings per share. Inogen’s revenue was up 3.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Inogen Inc will post 1.09 earnings per share for the current year.

In other Inogen news, Director Heath Lukatch acquired 2,000 shares of Inogen stock in a transaction that occurred on Thursday, August 15th. The stock was bought at an average cost of $43.01 per share, for a total transaction of $86,020.00. Following the acquisition, the director now owns 5,481 shares of the company’s stock, valued at $235,737.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.54% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund increased its holdings in Inogen by 1.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 7,029 shares of the medical technology company’s stock worth $670,000 after buying an additional 132 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Inogen by 1.4% during the 1st quarter. Arizona State Retirement System now owns 12,845 shares of the medical technology company’s stock valued at $1,225,000 after buying an additional 178 shares in the last quarter. Advisor Group Inc. lifted its position in shares of Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after buying an additional 192 shares in the last quarter. Mason Street Advisors LLC lifted its position in shares of Inogen by 2.9% during the 1st quarter. Mason Street Advisors LLC now owns 9,512 shares of the medical technology company’s stock valued at $907,000 after buying an additional 267 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of Inogen by 4.1% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 9,933 shares of the medical technology company’s stock valued at $663,000 after buying an additional 390 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: Futures Contract

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.